Prostate Cell News Volume 12.23 | Jun 25 2021

    0
    34







    2021-06-25 | PCN 12.23


    Prostate Cell News by STEMCELL Technologies
    Vol. 12.23 – 25 June, 2021
    TOP STORY

    Reactivation of the Tumor Suppressor PTEN by mRNA Nanoparticles Enhances Antitumor Immunity in Preclinical Models

    Investigators demonstrated that mRNA delivery by polymeric nanoparticles could effectively induce expression of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) in Pten-mutated melanoma cells and Pten-null prostate cancer cells.
    [Science Translational Medicine]

    Abstract

    Explore Antibodies for Epithelial Cell Markers
    PUBLICATIONSRanked by the impact factor of the journal

    MUC1-C Activates the PBAF Chromatin Remodeling Complex in Integrating Redox Balance with Progression of Human Prostate Cancer Stem Cells

    The authors revealed a role for MUC1-C in regulating PBAF, redox balance, and lineage plasticity of prostate cancer stem cell progression.
    [Oncogene]

    Full Article

    Diagnostic and Prognostic Potential of the Proteomic Profiling of Serum-Derived Extracellular Vesicles in Prostate Cancer

    Investigators exploited an antibody-based proteomic technology to measure key antigens and activated signaling in extracellular vesicles isolated from sera of prostate cancer patients.
    [Cell Death & Disease]

    Full Article

    Tumor Irradiation Combined with Vascular-Targeted Photodynamic Therapy Enhances Antitumor Effects in Pre-Clinical Prostate Cancer

    Scientists investigated whether sequential delivery of fractionated radiotherapy (FRT) followed by vascular-targeted photodynamic therapy (VTP) days later improved flank TRAMP-C1 prostate cancer tumor allograft control compared to monotherapy with FRT or VTP.
    [British Journal of Cancer]

    Full Article

    PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer

    Researchers analyzed the efficacy and mechanistic interactions of PARP inhibition and CDK4/6 inhibition (CDK4/6i) combination therapy in CRPC and neuroendocrine prostate cancer models.
    [Molecular Cancer Therapeutics]

    Abstract

    Androgen Receptor Variant Shows Heterogeneous Expression in Prostate Cancer According to Differentiation Stage

    The authors presented a single-circulating tumor cell (CTC) sensitive digital droplet PCR assay for the quantitation of the two most common androgen receptor variants (AR-Vs), AR-V7, and AR-v567es, using antigen agnostic CTC enrichment.
    [Communications Biology]

    Full Article

    MCM2-7 Complex Is a Novel Druggable Target for Neuroendocrine Prostate Cancer

    Inhibition of MCM2-7 by treatment with ciprofloxacin inhibited neuroendocrine prostate cancer (NEPC) cell proliferation and migration in vitro, significantly delayed NEPC tumor xenograft growth, and partially reversed the neuroendocrine phenotype in vivo.
    [Scientific Reports]

    Full Article

    Circular RNA circHIPK3 Modulates Prostate Cancer Progression via Targeting miR-448/MTDH Signaling

    Several studies have identified that circular RNAs (circRNAs) have a crucial impact on the biological processes in prostate cancer. Researchers studied the molecular mechanism of circRNAs in tumor progression and metastasis.
    [Clinical and Translational Oncology]

    Abstract

    A Proteomic Investigation of Isogenic Radiation Resistant Prostate Cancer Cell Lines

    To model the problem of radiation resistance in prostate cancer, cell lines mimicking a clinical course of conventionally fractionated or hypofractionated radiotherapy were generated.
    [Proteomics Clinical Applications]

    Abstract

    Explore virtual support and resources to stay productive and connected with your field.
    REVIEWS

    Prostate Cancer Cell Heterogeneity and Plasticity: Insights from Studies of Genetically-Engineered Mouse Models

    Scientists discuss recent advances in understanding the cell types of origin, putative cancer stem cells, and tumor plasticity in prostate cancer, focusing on insights from studies of genetically engineered mouse models.
    [Seminars in Cancer Biology]

    Abstract

    Exercise-Induced Myokines and Their Effect on Prostate Cancer

    Studies applying post-exercise blood serum directly to various types of cancer cell lines provide insight that exercise might have a role in inhibiting cancer growth via altered soluble and cell-free blood contents.
    [Nature Reviews Urology]

    Abstract

    INDUSTRY AND POLICY NEWS

    LYNPARZA® (Olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

    AstraZeneca and Merck announced that LYNPARZA ® has been granted conditional approval in China as monotherapy for the treatment of adult patients with germline or somatic BRCA-mutated metastatic CRPC who have progressed following prior treatment that included a new hormonal agent.
    [Merck]

    Press Release

    First Participant Dosed in Pfizer’s Pivotal Phase III TALAPRO-3 Combination Study of Talazoparib and Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

    Pfizer Inc. announced that the first participant has been dosed in TALAPRO-3, a global, randomized, double-blind, placebo-controlled Phase III clinical trial. The study will evaluate the efficacy and safety of talazoparib in combination with enzalutamide compared with placebo plus enzalutamide in men with DNA damage response-deficient mCSPC.
    [Pfizer Inc.]

    Press Release

    FEATURED EVENT

    AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    October 7 – 11, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Research Fellow – Molecular Pharmacology & Experimental Therapeutics

    Mayo Clinic Health System – Rochester, Minnesota, United States

    Epidemiologist – Prostate Disease Research

    Henry M Jackson Foundation for the Advancement of Military Medicine – Bethesda, Maryland, United States

    Postdoctoral Fellow – Cancer Pathogenesis

    Institute of Oncology Research – Bellinzona, Switzerland

    Research Investigator – Cancer Research

    University of Texas MD Anderson Cancer Center – Houston, Texas, United States

    Scientific Director – Prostate and Genitourinary Cancer Research

    Emory University – Atlanta, Georgia, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Prostate Cell News Twitter